[A26-31] Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 03.09.2026
Project no.:
A26-31
Commission:
Commission awarded on 16.03.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with metastatic hormone-sensitive prostate cancer (mHSPC) and breast cancer-associated gene (BRCA)1/2 mutations (germline and/or somatic)
- Patients with newly diagnosed high-risk mHSPC and BRCA1/2 mutations (germline and/or somatic): added benefit not proven
- All other patients in the therapeutic indication: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 15.06.2026.
https://doi.org/10.60584/A26-31_V1.1
| Project no. | Title | Status |
|---|---|---|
| A23-107 | Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A26-98 | Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A26-31 | Commission completed |
Federal Joint Committee (G-BA)
03-09-2026 A G-BA decision was published.
G-BA documents on this decision